Please login to the form below

Not currently logged in
Email:
Password:

FDA extends review period for ipilimumab

The US FDA has determined that additional time is required to complete the review of the biologics licence application for BMS' ipilimumab

Bristol-Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has determined that additional time is required to complete the review of the biologics licence application (BLA) for ipilimumab, which is used for pre-treated advanced melanoma.

The decision date has been moved from December 25, 2010 to March 26, 2011.

In response to an FDA request, BMS submitted further analysis of data pertaining to the current application for pre-treated advanced melanoma, and FDA considers this to be a major amendment to the drug's BLA.

BMS has said that it continues to be very encouraged by its interactions with the FDA and remains confident in the overall development programme for ipilimumab.

Ipilimumab is also currently under review with the European Medicines Agency (EMA) and other health authorities worldwide for pre-treated advanced melanoma.

3rd November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics